A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

according to Pfizer. Administering a third dose restores protective efficacy back up to 95% or more, it said. Meanwhile, Moderna also reported new data with its mRNA-1273 jab – which won't be ...

The company will compete in a market where GSK and Pfizer already have a presence. Earlier this month, Moderna released data ... to compare the safety and efficacy of its RSV shot with others ...

The FDA instead reviewed data that Pfizer and Moderna had collected from clinical studies of the safety and efficacy of earlier iterations of the shot, which had been targeted at the original Omicron ...

Moderna and Pfizer have both said that updated versions ... led to concerns that the current generation of shots may lack efficacy. It's encouraging, then, that Moderna's mRNA-1273.715 vaccine ...

Bourla and Afeyan said they began talking about this new approach in the depths of the pandemic, when they were “partners-slash-competitors,” as Bourla puts it, in the effort to create a vaccine.